KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Retained Earnings (2018 - 2025)

Elanco Animal Health's Retained Earnings history spans 9 years, with the latest figure at -$141.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 92.77% year-over-year to -$141.0 million; the TTM value through Dec 2025 reached -$141.0 million, up 92.77%, while the annual FY2025 figure was -$141.0 million, 92.77% up from the prior year.
  • Retained Earnings for Q4 2025 was -$141.0 million at Elanco Animal Health, up from -$199.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$102.0 million in Q1 2021 and bottomed at -$2.3 billion in Q2 2024.
  • The 5-year median for Retained Earnings is -$698.5 million (2021), against an average of -$913.6 million.
  • The largest annual shift saw Retained Earnings plummeted 783.33% in 2022 before it skyrocketed 92.77% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$209.0 million in 2021, then crashed by 87.56% to -$392.0 million in 2022, then tumbled by 483.67% to -$2.3 billion in 2023, then increased by 14.77% to -$2.0 billion in 2024, then surged by 92.77% to -$141.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Retained Earnings are -$141.0 million (Q4 2025), -$199.0 million (Q3 2025), and -$192.0 million (Q2 2025).